RESUMEN
Streptosotocin was administered to 21 test animals and 19 control ones. Preventively, the former were given T-activin, the latter--saline. 73% of the test animals were free of hyperglycemia, insulinopenia, activation of lipid peroxidation, morphologic evidence of beta-cell damage. In control animals diabetes mellitus arose in 84% manifesting with marked hyperglycemia, insulinopenia, LPO activation, morphological signs of beta-cell damage, lymphocytic infiltration of the islets. From the results obtained it can be concluded that T-activin has a prominent protective effect against diabetes mellitus (chi-square = 6.34, p < 0.05) which can be explained by its antioxidant and immunotropic activity.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Enfermedades Autoinmunes/prevención & control , Diabetes Mellitus Experimental/prevención & control , Péptidos/uso terapéutico , Extractos del Timo/uso terapéutico , Animales , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/etiología , Enfermedades Autoinmunes/patología , Glucemia/metabolismo , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/etiología , Diabetes Mellitus Experimental/patología , Evaluación Preclínica de Medicamentos , Insulina/sangre , Masculino , Páncreas/patología , Ratas , Ratas Wistar , Estadísticas no ParamétricasRESUMEN
Chemically pure hydroxyapatite (HA) with particles less than 140 microns, less than 60 microns, and 0.01 to 0.03 microns was studied. The immunoadjuvant properties were assessed from the count of IgM-secreting cells and titer of IgG antibodies. Mice were immunized with Salmonella Vi antigen, using mixtures of the antigen with HA with different size of particles. Preparations with particles less than 60 microns and 0.01 to 0.03 micron had a reliable immunoadjuvant effect, whereas HA with particles of up to 140 microns in size did not show such an effect; these data are in line with those published elsewhere about HA as a surfactant. At the same time, our findings give grounds to speak about new prospects of HA use as a carrier of immunocorrective properties.